Newsletter | July 28, 2026

07.28.26 -- STREAM Edition: Future CGT Manufacturing Trends, AI Reality Checks, And Phase 1 Strategy

SPONSOR

 

Webinar: Rewriting the Code: Advances and Challenges in Pediatric Gene Therapy

Pediatric gene therapy is rapidly transforming treatment for rare genetic diseases. Join Dr. Rachel Abu Taleb as she explores AAV, lentiviral, and CRISPR platforms, reviews lessons from approved therapies, and examines the scientific, regulatory, and access challenges shaping future innovation. Learn how these advances are redefining care and improving outcomes for children with rare diseases. Click here to learn more.

Closing Ancillary Processes: The New Bottleneck In Cell and Gene Therapy

Video | Invetech

One continued challenge for scalable commercial cell therapy manufacturing is closing and automating the entire process. Many core processes may be closed, but peripheral systems remain vulnerable.

Bridging The Gap Between Lab Development And GMP Manufacturing

Video | Cell & Gene

Expert panelists Pratik Jaluria, Ph.D., SVP TDS at BlueRock Therapeutics, Bruno Marques, Ph.D. VP, P&PD at Century Therapeutics, and Kate Rochlin, Ph.D., COO at IN8bio, discuss best practices for translating lab development processes into cGMP manufacture settings.

Non-Viral CAR T Manufacture With Electroporation And Microbubble Isolation

Webinar | MaxCyte, Inc.

Unlock superior non-viral CAR T manufacturing outcomes by combining gentle microbubble T cell isolation with advanced electroporation. See how this approach boosts cell viability and transfection efficiency.

Characterizing AAV Encapsidated Nucleic Acid Sequences Using NGS

Webinar | MilliporeSigma

Discover how next-generation sequencing and targeted bioinformatic pipelines characterize encapsidated DNA to provide a clearer picture and ensure vector consistency and safety.

AAV Analytics: Key Considerations When Developing A Clinical Program

Webinar | Andelyn Biosciences

Finding partners with the necessary skills to optimize AAV processes is crucial for minimizing risk. Explore key considerations for advancing your therapy from concept to commercialization.

Future CGT Manufacturing Trends, AI Reality Checks, And Phase 1 Strategy

Video | Cell & Gene

This segment features Omkar Kawalekar, Ph.D., M&SC Lead, Deloitte Consulting, and Zoe Zheng, ED, PTS Lead, Legend Biotech, discussing the innovations most likely to impact CGT commercialization, such as closed automated platforms, AI-driven analytics and predictive release, and digital orchestration.

Connect With Cell & Gene: